Dr. Wei Li, Ph.D., serves as Acting Chief Executive Officer of AltheaDx, Inc. Dr. Li is a Founding Partner and Managing Partner at Wuxi Healthcare Ventures. He is an Executive Partner of China at Eight Roads Ventures China. He was an Executive Partner of China at Fidelity Growth Partners Asia. He has over 20 years of experience as a successful executive and entrepreneur in the biotech industry. Prior to joining WuXi Healthcare Ventures, Dr. Li focused his effort on healthcare and life science investment opportunities at Fidelity Biosciences, Fidelity Growth Partner Asia, and Baird Venture Partners. Dr. Li was an Executive Partner of China at Fidelity Biosciences. He served as a Principal and a Senior Associate at Fidelity Biosciences. He joined Fidelity in 2005, Dr. Li served as an Associate at Baird Venture Partners, where he focused on investments in healthcare and life sciences sectors. Dr. Li led several drug discovery projects and conducted technology licensing due diligence at Vertex Pharmaceuticals where he served as a Senior Manager. He also worked in strategic marketing at Serono International S.A. He Co-founded Innovent Bio. Dr. Li serves as a Director of TCR2 Therapeutics Inc., AltheaDx, Inc. and MDDF. He serves as an Observer at Nutrinia Ltd. He served on the Board of Directors of TCT Medical and Innovent Biologics. During his scientific research career, Dr. Li has first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry. He received a B.S., with distinction in Chemical Physics from the University of Science and Technology of China and holds a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University. Dr. Li also holds an M.B.A. from the Kellogg School of Management at Northwestern University where he was elected beta gamma sigma with concentrations in Finance, Accounting, and Marketing.